Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

HAEMATOLOGICAL CANCER

Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy

Nature Reviews Clinical Oncology volume 18, pages 677–678 (2021)Cite this article

Subjects

Chimeric antigen receptor (CAR) T cells have remarkable efficacy in patients with B cell acute lymphoblastic leukaemia (ALL), but have not been successful to date in patients with T cell ALL (T-ALL). Now, data from Pan and colleagues demonstrate the safety and impressive short-term efficacy of allogeneic donor-derived anti-CD7 CAR T cells in an early-phase clinical trial involving patients with relapsed and/or refractory T-ALL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Teachey, D. T. & Hunger, S. P. Acute lymphoblastic leukaemia in 2017: immunotherapy for ALL takes the world by storm. Nat. Rev. Clin. Oncol. 15, 69–70 (2018).

    Article  Google Scholar 

  2. Bayón-Calderón, F., Toribio, M. L. & González-García, S. Facts and challenges in immunotherapy for T-cell acute lymphoblastic leukemia. Int. J. Mol. Sci. 21, 7685 (2020).

    Article  Google Scholar 

  3. Pan, J. et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J. Clin. Oncol. https://doi.org/10.1200/jco.21.00389 (2021).

    Article  PubMed  Google Scholar 

  4. Greenman, J., Jones, E., Wright, M. D. & Barclay, A. N. The use of intracellular single-chain antibody fragments to inhibit specifically the expression of cell surface molecules. J. Immunol. Methods 194, 169–180 (1996).

    Article  CAS  Google Scholar 

  5. Teachey, D. T. & Pui, C. H. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 20, e142–e154 (2019).

    Article  Google Scholar 

  6. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).

    Article  Google Scholar 

  7. Wang, X. et al. First-in-human, universal anti-CD7 CAR-T therapy for relapsed and refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). Proc. Eur. Soc. Haematol. Ann. Meeting 2021 5, S115 (2021).

    Google Scholar 

  8. Zhang, M. et al. First-in-class autologous CD7-CAR-T cells exhibited promising clinical efficacy for relapsed and refractory T-lymphoblastic leukemia/lymphoma [abstract 973]. American Society Hematology https://ash.confex.com/ash/2020/webprogram/Paper136508.html (2020).

  9. DiNofia, A. M. & Grupp, S. A. Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells ‘off the shelf’? Nat. Rev. Clin. Oncol. 18, 195–196 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    David T. Teachey & Stephen P. Hunger

  2. The Center for Childhood Cancer Research, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    David T. Teachey & Stephen P. Hunger

Authors
  1. David T. Teachey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen P. Hunger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen P. Hunger.

Ethics declarations

Competing interests

D.T.T. serves on the scientific advisory boards of BEAM Therapeutics, Janssen, La Roche and Sobi; receives research funding from Leukemia and Lymphoma Society and Neoimmune Tech; and has a patent pending on biomarkers for cytokine-release syndrome (US2018025272A1). S.P.H. owns stock in Amgen and has received honoraria for lectures from Amgen and Jazz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Teachey, D.T., Hunger, S.P. Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy. Nat Rev Clin Oncol 18, 677–678 (2021). https://doi.org/10.1038/s41571-021-00556-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-021-00556-3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer